Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer

[11] Bezwoda WR(2010) Clinical evaluation of NK 622 (toremifen citrate) in advanced or recurrent breast cancer—a comparative study by a double blind method with tamoxifen Jpn Clin Oncol 40 627-633

[12] Mailliard JA(1996)Effect of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial J Natl Cancer Inst 88 1543-1549

[13] Gershanovichi M(1996)Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer J Natl Cancer Inst 88 1529-1542

[14] Garin A(2000)Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Clin Oncol 18 3487-3494

[15] Baltina D(2000)Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer Breast Cancer Res Treat 65 119-134

[16] Kurvert A(2004)Phase III randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer Ann Oncol 15 1749-1759

[17] Kangas L(2010)Toremifene and tamoxifene are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Cancer 116 2307-2315

[18] Ellman J(1999)Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer Breast Cancer Res Treat 56 133-143

[19] Pyrhönen S(2003)Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer N Engl J Med 348 618-629

[20] Valavaara R(2004)Selective estrogen-receptor modulators mechanisms of action and application to clinical practice Breast Cancer Res Treat 88 1-8

[11] Bezwoda WR(2010) Clinical evaluation of NK 622 (toremifen citrate) in advanced or recurrent breast cancer—a comparative study by a double blind method with tamoxifen Jpn Clin Oncol 40 627-633

[12] Mailliard JA(1996)Effect of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial J Natl Cancer Inst 88 1543-1549

[13] Gershanovichi M(1996)Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer J Natl Cancer Inst 88 1529-1542

[14] Garin A(2000)Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Clin Oncol 18 3487-3494

[15] Baltina D(2000)Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer Breast Cancer Res Treat 65 119-134

[16] Kurvert A(2004)Phase III randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer Ann Oncol 15 1749-1759

[17] Kangas L(2010)Toremifene and tamoxifene are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Cancer 116 2307-2315

[18] Ellman J(1999)Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer Breast Cancer Res Treat 56 133-143

[19] Pyrhönen S(2003)Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer N Engl J Med 348 618-629

[20] Valavaara R(2004)Selective estrogen-receptor modulators mechanisms of action and application to clinical practice Breast Cancer Res Treat 88 1-8